Skip to content


  • Letter
  • Open Access

Rapid detection of carbapenem resistance: targeting a zero level of inadequate empiric antibiotic exposure?

Critical Care201620:404

  • Published:


  • Multidrug-resistant bacteria
  • Carbapenem resistance
  • Polymerase chain reaction

Resistance to carbapenems is an increasingly encountered phenomenon in the ICU, complicating empiric and targeted antimicrobial therapy. Infections due to carbapenem-resistant microorganisms are characterized by high morbidity and mortality [1, 2]. Recently, there has been an increasing interest in rapid detection techniques, based on real time on-demand easy-to-use PCR, to detect genes responsible for carbapenem resistance. One of these techniques is the Cepheid Xpert Carba-R assay, which is able to detect and differentiate five of the most frequent genes associated with non-susceptibility to carbapenems in Gram-negative bacteria (bla KPC , bla VIM , bla OXA-48 , bla IMP-1 , bla NDM ). The diagnostic performance of this assay seems to be high when compared to classic microbiological cultures and gene identification with in-house PCR in a clinical setting, especially in intra-abdominal infections using samples from rectum or abdominal drainage material [3, 4]. Originally, assays for screening of patients carrying multidrug-resistant organisms were used to guide infection control programs, to restrict access to patients’ health-care zones, or for outbreak surveillance. However, several studies reported an association between detection from surveillance techniques and subsequent infection etiology, improving the rate of adequate empiric antimicrobial treatment [5].

The Xpert Carba-R assay delivers results in less than 1 hour. It might be argued that the identification of genes associated with non-susceptibility at the beginning of therapeutic decision-making, when clinicians are deciding whether to add carbapenems or not, may lower the rate of inadequate use of these antimicrobials, to which resistance rates are continuously increasing. This application would shift the utility of this technique from screening to an active part of therapeutic decision-making. To date, two aspects may limit its application. First, although it is able to detect five of the most common genes, clinicians should carefully evaluate which are the genetic determinants of carbapenem-resistance in their ICU to optimize diagnostic performance. Second, the data came from rectal swabs and material from abdominal drainage and the clinical usefulness in other clinical settings should be tested.

Following this road, we may hope to obtain, in the near future, information on genes associated with resistance to antibiotics by easy-to-use, on-demand techniques before starting therapies and reducing inadequate empiric treatment to nearly zero.



Polymerase chain reaction





The authors did not receive any funding for this article.

Availability of data and material

Not applicable.

Authors’ contributions

AC, VR, PI, SMR, and AG conceived the content of the letter. AC and VR wrote the text. All authors read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethical approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anaesthesia, Analgesia, Intensive Care and Emergency, University Hospital Paolo Giaccone, University of Palermo, Via del vespro 129, 90127 Palermo, Italy
Intensive Care Unit, University Hospital Paolo Giaccone, University of Palermo, Via del vespro 129, 90127 Palermo, Italy


  1. Karam G, Chastre J, Wilcox MH, Vincent J-L. Antibiotic strategies in the era of multidrug resistance. Crit Care. 2016;20:136.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Russotto V, Cortegiani A, Graziano G, Saporito L, Raineri SM, Mammina C, et al. Bloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteria. Infect Drug Resist. 2015;8:287–96.PubMedPubMed CentralGoogle Scholar
  3. Tato M, Ruiz-Garbajosa P, Traczewski M, Dodgson A, McEwan A, Humphries R, et al. Multisite evaluation of Cepheid Xpert Carba-R assay for detection of carbapenemase-producing organisms in rectal swabs. J Clin Microbiol. 2016;54:1814–9.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Cortegiani A, Russotto V, Graziano G, Geraci D, Saporito L, Cocorullo G, et al. Use of Cepheid Xpert Carba-R(R) for rapid detection of carbapenemase-producing bacteria in abdominal septic patients admitted to intensive care unit. PLoS One. 2016;11:e0160643.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Papadomichelakis E, Kontopidou F, Antoniadou A, Poulakou G, Koratzanis E, Kopterides P, et al. Screening for resistant gram-negative microorganisms to guide empiric therapy of subsequent infection. Intensive Care Med. 2008;34:2169–75.View ArticlePubMedGoogle Scholar


© The Author(s). 2016